Oncolytics Biotech Inc T.ONC

Novartis announces 2nd stock buyback plan

[Noteable]

This time, the new plan coincides with an expected spinoff of Novartis’ generics unit Sandoz

https://www.fiercepharma.com/pharma/novartis-unveils-another-15b-share-buyback-despite-entresto-legal-setback

[Noteable]

Correspondingly, Novartis has dumped its secretive, high-risk, high-reward obesity candidate after emerging from a phase 2 trial with lackluster efficacy. The Swiss drugmaker disclosed the termination alongside news that it is stopping development of a phase 3 pancreatic cancer candidate “based on benefit-risk assessment.”  The other high-profile casualty of Novartis’ second

[Noteable]

The plausible reason for Novartis to terminate its late stage Phase 3 pancreatic cancer clinical trial with its TGFB specific antibody is because this antibody, like other antibodies, is a small molecule drug. And since the recently passed Inflation Reduction Act (IRA) only provides 9 years of FDA market exclusivity from the date of approval for small molecules versus to 13 Years for novel